User profiles for S. Marchand-Adam

sylvain marchand-adam

professeur de pneumologie
Verified email at univ-tours.fr
Cited by 8135

Comorbidities of COPD

…, C Gut-Gobert, S Marchand-Adam… - European …, 2013 - Eur Respiratory Soc
… The impact of obstructive airway disease, defined by a decrease in the ratio of forced expiratory
volume in 1 s (FEV 1 ) to forced vital capacity (FVC), is less clear-cut, as it only increases …

Pulmonary manifestations of Sjögren's syndrome

…, H Henique, E Diot, S Marchand-Adam - European …, 2016 - Eur Respiratory Soc
… Diot and S. Marchand-Adam were responsible for the conception and design. All authors
were responsible for analysis and interpretation, and drafting the manuscript and revision for …

[HTML][HTML] Physiology of the lung in idiopathic pulmonary fibrosis

…, C Bancal, S Marchand-Adam… - European …, 2018 - Eur Respiratory Soc
… 3–5], IPF is a very severe disease where clinical decline is common. IPF is of particular interest
to … failure, is directly related to alterations in lung physiology. The aim of the present article …

Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised …

…, TM Maher, S Makino, S Marchand-Adam… - The lancet Respiratory …, 2020 - thelancet.com
Background The INBUILD trial investigated the efficacy and safety of nintedanib versus
placebo in patients with progressive fibrosing interstitial lung diseases (ILDs) other than …

Extracellular ATP Is a Danger Signal Activating P2X7 Receptor in Lung Inflammation and Fibrosis

…, VFJ Quesniaux, S Marchand-Adam… - American journal of …, 2010 - atsjournals.org
Rationale: Pulmonary fibrosis is a devastating as yet untreatable disease. We previously
investigated the endogenous mediators released on lung injury and showed that uric acid is a …

[HTML][HTML] MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

…, MC Boissier, S Marchand-Adam… - … England Journal of …, 2018 - Mass Medical Soc
Background Given the phenotypic similarities between rheumatoid arthritis (RA)–associated
interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we …

Methotrexate and rheumatoid arthritis associated interstitial lung disease

…, RM Flipo, S Marchand-Adam… - European …, 2021 - Eur Respiratory Soc
Question addressed by the study Methotrexate (MTX) is a key anchor drug for rheumatoid
arthritis (RA) management. Fibrotic interstitial lung disease (ILD) is a common complication of …

Shared genetic predisposition in rheumatoid arthritis-interstitial lung disease and familial pulmonary fibrosis

…, S Ottaviani, S Marchand-Adam… - European …, 2017 - Eur Respiratory Soc
… Specifically, interstitial lung disease (ILD) is the leading cause of mortality, accounting for
a mortality rate that is approximately 13% higher in RA patients as compared to the general …

Cutting edge: nonproliferating mature immune cells form a novel type of organized lymphoid structure in idiopathic pulmonary fibrosis

…, Y Uzunhan, S Marchand-Adam… - The Journal of …, 2006 - journals.aai.org
… IPF, showing that this process is not restricted to classical autoimmune diseases. They also
provide evidence that lymphoid neogenesis in IPF is fundamentally different from that usually …

Role of atmospheric pollution on the natural history of idiopathic pulmonary fibrosis

…, S Marchand-Adam, S Guillot-Dudoret, A Nardi, S Dury… - Thorax, 2018 - thorax.bmj.com
… levels of ozone is a risk factor for AE and demonstrate, for the first time, that long-term
exposure to elevated levels of PM 10 and PM 2.5 is a risk factor for mortality in patients with IPF. …